>
State of Play is a read on a sector: its size, its structure, where the money moves and what moves it. Each edition takes one market and sets out what is known, what is claimed, and what the difference between the two is worth to anyone deciding where to commit.
The world’s heaviest disease burden meets a market that can buy any device and make almost none, and the sovereign capital now trying to change that. The Gulf’s medical-technology market read in full: the disease burden that drives it, the import dependence that defines it, and the sovereign capital trying to localise it.
Figures carry their basis and their date. Where published estimates disagree, the range is given and the basis named rather than averaged away, and where a widely quoted number does not survive checking it is corrected here rather than repeated. Every chart plots a figure stated in the text, and nothing is projected beyond what a named source projects.
A single gap drives everything that follows: the world’s heaviest demand for medical devices, met by one of its smallest abilities to make them.
The Gulf carries one of the planet’s heaviest per-capita disease burdens. Diabetes rates are among the highest on earth, and cardiovascular disease is the leading killer. It pays for the treatment without flinching, the state footing a bill heading toward $159 billion a year by 2029. And yet it makes almost none of the instruments that treatment needs. Saudi Arabia imports about 94% of its medical devices, the UAE around 98%. That gap, lavish and well-funded demand against near-total import dependence, is the defining feature of Gulf medtech. The whole strategic contest is the fight to close it.
The fight is unlike any other market’s, because the Gulf is trying to buy its way to a domestic industry with sovereign capital. Saudi Arabia’s Public Investment Fund, Abu Dhabi’s Mubadala and ADQ, Qatar’s QIA: all are deploying state wealth and localisation mandates (regional-headquarters
rules, local-content preferences, central procurement) to turn the import bill into home-grown capability. The attempt has three consequences.
The Gulf medtech opportunity is thus the richest demand in the world bolted to the thinnest supply. Value goes to whoever helps convert the import bill into local capability, on the sovereign’s terms.
Two conditions should be added, and both sharpen the argument. The first is the comparator for the disease burden, which the chapter leaves implied. Adult diabetes prevalence across the six states runs from 18.7 to 25.6 per cent on the International Diabetes Federation's 11th edition, published in 2025 on 2024 estimates. The global rate is 11.1 per cent. At its lowest the regional figure is more than half again the world rate, and at its
highest well above twice it. The re-based series also reorders the region, Qatar now standing second ahead of Saudi Arabia.
The second is the magnitude of the capital arrayed against the gap. The Gulf's largest sovereign funds command in the order of $5 trillion, a figure expected to approach $18 trillion by 2050. The Public Investment Fund, Mubadala and the Qatar Investment Authority deployed close to $25 billion between them in a single quarter of 2025. No comparable concentration of patient capital is available to any other import-dependent device market. That is why the Gulf case is not a variation on the Indian or South-East Asian one.
The contest is also narrower than the regional framing suggests. Of roughly 400 Gulf healthcare transactions recorded between 2021 and April 2025, Saudi Arabia and the UAE accounted for about 92 per cent. Whatever industry is built will therefore be built in two markets, and the remaining four will participate as buyers and as partners in pooled procurement.
The regulator's own licensing ledger states the condition more plainly than any trade statistic. At the end of 2025 the Saudi Food and Drug Authority held 9,155 licensed facilities across all its sectors, against 7,750 a year earlier. Within the medical devices sector it licensed 25 factories and 1,313 warehouses (Saudi Food and Drug Authority, 2026). One factory for every fifty-two warehouses. A register which grows mainly in storage describes an import and distribution economy rather than an industrial one.
The same ratio explains why licence counts flatter the localisation story. Warehouse permits follow import volume and import volume follows the hospital build-out, so a register expanding at eighteen per cent in a single year can be read as industrial progress when it is in fact rising throughput (Saudi Food and Drug Authority, 2026). The question to put to any localisation claim is which of the two lines it moves. Factories, or warehouses. Only one of them narrows the gap this read is about.
The Gulf spends like a patient who can afford any treatment, and cannot make the instruments of its own care.
Treated as a single patient, the Gulf would be wealthy and ageing, carrying one of the heaviest disease loads in the world, with the means to pay for any care it needs. It spends prodigiously. Regional health expenditure is on track from about $109 billion in 2024 to $159 billion by 2029, growing nearly 8% a year, and the state pays the bill. The “$5 trillion” of the title is rhetorical, the cumulative weight of a region pouring vast sums into its own health. The literal medtech market is a more modest $11 to $17 billion. But the metaphor holds. The Gulf is a formidable buyer of medical technology.
What it is not is a maker. The defining fact of Gulf medtech is the chasm between this lavish, state-funded demand and an almost non-existent domestic supply. Saudi Arabia imports roughly 94% of its devices, the UAE around 98%. The patient can buy the finest scanner, the newest implant, the most advanced dialysis machine; it produces virtually none of them. The gap is the subject of this read: why it exists, what it costs, and how sovereign capital is now trying to close it.
The patient's means are uneven, and the unevenness governs how the market is approached. Gross domestic product per head ranges from about $23,000 in Oman to roughly $81,000 in Qatar, among the highest figures in the world. Current health expenditure runs from 2.6 per cent of GDP in Qatar to 6.0 per cent in Oman (Gulf Health Economics Association, 2024). Dubai alone spends around $1,200 per head. Willingness to pay is therefore high across the region. The fiscal headroom behind it differs by a factor of three.
Installed capacity is thinner than the spending implies, and that gap is itself a demand driver. Hospital beds run at only 1.2 to 2.2 per 1,000 population and physicians at 1.0 to 3.1 per 1,000 (World Bank, 2017 to 2021), both below developed-market norms, against life expectancy of 74 years in Oman and 82 in Qatar. A wealthy population with premium care standards and sub-OECD capacity sustains a continuous build-out of facilities and equipment rather than a one-off replacement cycle.
The cost of the burden has been quantified in at least one disease. Diabetes alone cost the six states more than $13.2 billion in 2019, which is of
the same order as the entire regional device market on a narrow definition. The metaphor of the title therefore holds in a more exact sense than rhetoric: the patient's treatment bill for one condition approaches the value of all the instruments used to treat every condition.
There is no single trustworthy figure for the Gulf device market, only a band, and a warning not to mistake it for the region around it.
The Gulf medical-device market resists precise sizing, and an honest read admits it. Estimates for 2024 run from about $11.3 billion (Statista’s conservative, internally-consistent measure) to about $17.2 billion (Market Research Future’s broader basket). The spread is driven not by error but by definition, by whether the figure folds in in-vitro diagnostics, consumables and digital health. The defensible framing is the band: roughly $11 to $17 billion in 2024, growing 6 to 7% a year toward the early 2030s.
Two cautions for anyone sizing the prize. First, never mistake the GCC for the wider Middle East and Africa. Figures of $11 billion (Grand View, Middle East) or $24.6 billion (Fortune, MEA) describe larger geographies and must not pass for Gulf-only. Second, Saudi Arabia and the UAE dominate, together more than 80% of regional health spending, Saudi alone around
60%, so “the Gulf market” is really two large markets and four small ones. The cleaner anchor than any device estimate is the health-expenditure backdrop, which is well-sourced and unambiguous: up, fast, and state-driven.
The band should be widened at the lower bound. On the reconciled basis now carried internally, a narrow device definition sits near $8.3 billion for 2025. A broad medical-equipment definition reaches about $17.15 billion for 2024, so the defensible range is roughly $8 to $17 billion rather than $11 to $17 billion. Growth of about 7 per cent a year takes the broad basis to approximately $36.21 billion by 2035, a multiple of about 2.1 times. The floor moves with the definition, not with the evidence.
The country figures carry the same hazard in a sharper form, and it is a hazard of arithmetic rather than of reporting. Per-country values are drawn from different research houses on different scopes and are not
strictly comparable. The UAE figure of about $3.8 billion for 2024 rests on a broad basis, while Saudi Arabia's $2.34 billion for the same year rests on a device basis. Read without that flag, the series appears to show the UAE as the larger market, which no source actually claims. Country values should never be summed to a regional total.
Growth is fastest where the market is least like hardware. Wearable health devices are projected to rise from about $1.05 billion toward $3.12 billion by 2032, roughly 17 per cent a year and more than twice the market average. That is the clearest numerical sign that the fastest segment of Gulf medtech is also the one least gated by manufacturing.
The single defining number of Gulf medtech is the share it does not make, and it is almost everything.
Import dependence is the heart of this read, and the Gulf wears it more starkly than almost anywhere. Saudi Arabia, the region’s largest market, imports about 94% of its device demand, on figures from the official Saudi Industrial Center. That is against a domestic market of roughly SAR 20 billion served by some 45 local manufacturers holding perhaps 6% of it. The UAE is more dependent still, importing an estimated 98%, its local
production limited to prototypes, spare parts and basic disposables like gloves and syringes.
The dependence has a shape. High-value devices come overwhelmingly from the United States and Germany, with Japan and China climbing. Those are the imaging systems and the implants, along with surgical robotics and diagnostic equipment. What little the Gulf makes sits at the low-value end, in consumables and commodities. Saudi Arabia’s own framing is candid, the country is “repositioning from a manufacturer of low-value commodities (bandages, gloves, syringes) to high-value medical products,” which is an admission that, today, the high-value end is imported wholesale. No source pins a single precise GCC-wide figure, but the country numbers leave no doubt. In medical devices, the Gulf is a buyer, and almost nothing else.
A share of spending is the better measure than a count of factories, and on that measure the dependence is starker still. Region-wide, about 96 per cent of medical devices are imported, chiefly from the United States and
Germany, and less than 3 per cent of Saudi device spending reaches locally made product, almost all of it low-technology consumables. A licence count rewards permits; a spend share weights value, and it is the spend share that measures the prize.
The dependence also runs below the level of the finished device. Components, intellectual property and high-end capital equipment are almost wholly external, so even the modest local assembly that exists relies on imported inputs. The consequence is that localising final assembly moves the import line down the bill of materials rather than off it, and any claim of local content must be read against the origin of the components.
The shape of the dependence maps cleanly onto device category. It is near-total in imaging and radiology, and very high in surgical and
orthopaedic implants and in cardiac and vascular devices. Dependence is high in in-vitro diagnostic instruments and reagents and in patient monitoring. It is moderate only in consumables and disposables, where the limited local production sits. Software as a medical device stands outside the logic entirely, being gated by talent and data rather than by manufacture.
This burden is the engine of device demand, and it is structural, not cyclical, the product of rapid lifestyle transition, diet and demographics, not a passing shock. Its consequences cascade straight into specific device markets: diabetes and hypertension drive end-stage renal disease and a vast dialysis-equipment need; cardiovascular disease drives cardiac devices and imaging; obesity drives metabolic and surgical demand. Saudi Arabia is already the Gulf’s largest diabetes-care-device market. The
demand side of Gulf medtech needs no speculation. It is visible, measured, and among the most acute in the world.
The demand that funds all of this is not a forecast. It is a present, measured, exceptional disease load.
The Gulf spends so much on medical technology because, by several measures, it is among the sickest populations on earth for chronic disease. Diabetes is the headline: on the International Diabetes Federation’s age-standardised figures for 2024, Kuwait runs at 25.6% of adults, among the highest rates anywhere. Qatar is at 24.6%, Saudi Arabia at 23.1%, Bahrain at 22.1%, the UAE at 20.7% and Oman at 17.0%. Obesity tracks alongside, Kuwait, Saudi Arabia and Qatar all near the global top. Cardiovascular disease is the leading cause of death across the region, roughly 45% of all deaths.
The figures above are the International Diabetes Federation's 11th edition, published in 2025 on 2024 estimates, on age-standardised comparative prevalence for adults aged 20 to 79. The citation needs stating precisely. The 9th-edition series has been superseded and is still widely quoted. The comparator that gives the figures meaning is a global rate of 11.1 per cent. The superseded values put the Gulf range at about 15 to 22 per cent. On
the re-based series Qatar ranks second, ahead of Saudi Arabia, a reordering that any country-level reading must now reflect.
The wider burden is quantified on the same basis. Adult obesity runs from roughly 23 per cent in Oman to about 38 per cent in Kuwait, and diabetes alone cost the six states more than $13.2 billion in 2019. The cancer burden is the fastest-moving component. An estimated 42,475 new cases were recorded in 2020, at age-standardised incidence of about 96.5 and mortality of about 52.3 per 100,000. The caseload is projected to rise by between 116 per cent in Saudi Arabia and 270 per cent in Qatar, reaching roughly 104,000 cases by 2040 (Alessy and others, 2024).
Demography compounds all of it. A maturing citizen population and large expatriate workforces continuously broaden the patient base, so the
burden is additive rather than cyclical, and the device categories it feeds are precisely those the region cannot yet make.
A disease burden becomes a device market through a specific, traceable chain, and the Gulf’s runs at full strength.
Sickness converts into device demand along a chain worth tracing, because it shows exactly where the Gulf’s spending lands. It starts with the metabolic burden, world-leading diabetes and obesity, and runs through the complications to the equipment that treats them:
The chain matters because it tells a maker or investor precisely which categories the Gulf’s epidemiology guarantees demand for, whatever the
economic cycle does. Those categories are dialysis and cardiac work, together with diabetes management and imaging. It is also the chain localisation policy aims at. If the Gulf must import the very devices its own disease profile demands, the import bill is at once the cost of the disease and the map of the localisation prize.
The chain can be set against a formal category framework, which is how the internal record reads it. Eight device categories carry the analysis. They are in-vitro diagnostics; surgical and orthopaedic; imaging and radiology; cardiac and vascular; patient monitoring and wearables; software as a medical device and artificial intelligence; consumables and disposables; and a residual group covering ophthalmic, dental, ENT and related fields. Each is read on three axes: regulatory risk class, degree of import dependence, and strength of regional demand.
Read that way, the chain terminates in the categories hardest to localise. In-vitro diagnostics carries the largest demand, driven by diabetes and chronic disease, with recurring reagent revenue and point-of-care testing as the first realistic localisation opening. Cardiac and vascular devices sit in the highest risk classes and carry very high import dependence. Imaging is near-total in its dependence. It is also capital-intensive, which is why the hospital build-out converts so directly into import volume. Monitoring and wearables is the fastest-growing category of the eight.
The oncology leg of the chain deserves separate weight, since it is the one growing fastest from a low base. A caseload projected to roughly
double and more across the region by 2040 pulls oncology, imaging and radiotherapy equipment in particular. Medical tourism adds a further pull toward accreditation-grade equipment, concentrated in the UAE.
Most emerging markets are gated by who can pay. The Gulf is not. The state pays, and that changes everything.
The structural advantage of Gulf medtech is the one most emerging markets lack. It has a payer. Across all six states, the government funds universal care for nationals, and the state is both the dominant payer and the dominant buyer of medical technology. On top of that sits mandatory private health insurance, mainly for the large expatriate populations. It runs through Saudi Arabia’s Council of Cooperative Health Insurance, the long-standing mandates in Abu Dhabi and Dubai, and, from January 2025, an extension of compulsory cover to all the northern emirates, so every emirate now enforces it.
This architecture is why Gulf demand is so dependable. Where Indian or African device markets live or die on what patients can pay out of pocket, Gulf demand is underwritten by sovereign budgets and insurance
mandates, so it converts straight into procurement. It also concentrates power: because the state buys most of the devices, through the central procurement bodies, it can set terms, including the localisation preferences that run through this read. The payer is the Gulf’s great strength on the demand side and, through its purchasing power, the chief lever of its localisation ambition on the supply side. Here, the buyer and the policymaker are the same entity.
The payer's commitment is better read from budget share than from the share of GDP, because hydrocarbon output distorts the denominator. Current health expenditure ranges from 2.6 per cent of GDP in Qatar to 6.0 per cent in Oman (Gulf Health Economics Association, 2024), which appears to rank Qatar last. Yet Qatar allocates close to 11 per cent of its national budget to health. The inverse relationship between wealth and health share of GDP is therefore an artefact of the denominator, and the GDP ratio should not be used to rank state commitment.
The insurance mandates extend further than the Emirates, and two of them are still arriving. Bahrain's SEHATI programme, established under Law No. 23 of 2018 and overseen by the Supreme Council of Health, obliges employers to cover non-Bahraini workers. The roll-out is still phased. Oman's Dhamani platform was launched by the Financial Services Authority on 1 January 2025, connecting insurers and private providers electronically and broadening private-sector demand in the region's most publicly funded system. In both cases the financing reform, not the disease burden, is the proximate driver of new private demand.
The buyer's power is exercised through registration as much as through tender. In Saudi Arabia a foreign manufacturer must hold registration with
both the Saudi Food and Drug Authority and the National Unified Procurement Company before it may compete at all. The payer therefore controls not only the award but the right to bid for it.
The commitment can now be read directly off the appropriation rather than inferred from ratios. Saudi Arabia allocated 259 billion riyals to health and social development for 2026, the largest single sectoral line in a budget carrying 1.31 trillion riyals of expenditure, and well ahead of the 202 billion riyals given to education (Saudi Ministry of Finance, 2026). The line came in slightly below the previous year. Suppliers should note the direction of travel. Growth in Gulf health appropriations is no longer automatic, even where the insurance mandate is.
The insurance side of the architecture is better understood through its composition than through its total. The Council of Health Insurance put private cover at more than thirteen million people (Council of Health Insurance, 2025). About 7.2 million of them are non-Saudi principal beneficiaries and 1.4 million their dependants, against two million Saudi principals and 2.4 million dependants. Expatriate lives thus carry around two-thirds of the pool. Benefit design follows that weighting. It is why private formularies and device schedules track working-age conditions more closely than they track the ageing citizen population.
Two movements in the mandate are worth dating precisely. Kuwait doubled its compulsory expatriate health premium to 100 dinars a year with effect from 23 December 2025, which turns a nominal scheme into a
funded one (Middle East Insurance Review, 2025). In the Emirates, Daman reached an insured membership of 3.4 million in the first half of 2026 on gross written premium of 5.5 billion dirhams (PureHealth, 2026). The mandate is widening. The premium pool is deepening too. Both effects raise the share of procurement that reaches a supplier through an insurer rather than through a ministry.
The Gulf is building hospitals and beds at a pace few regions match, and every bed is a device order.
The demand chain is being met with one of the most ambitious healthcare build-outs on earth, and the scale of it is the device opportunity. Regional health spending climbing from $109 billion to $159 billion by 2029 funds a physical expansion. The Gulf needs an estimated 12,317 new hospital beds between 2024 and 2029, reaching roughly 140,600, with Saudi Arabia accounting for around 69% of the additions. Every new bed, ward and hospital is a stream of device orders. Those orders are for imaging and monitoring, and for surgical and laboratory equipment.
The build-out is uneven, and the unevenness is telling. Saudi Arabia, with the region’s fastest health-spending growth at around 8.8% a year, is the centre of gravity; the UAE follows; Qatar is repeatedly cited as the fastest-growing national market. The expansion is also tilting from purely public provision toward public-private partnerships and privatised delivery, which changes who buys the devices and how. For a maker, the build-out is the near-term demand signal, a defined, funded, multi-year pipeline of new capacity that has to be equipped. It is why Gulf medtech grows almost regardless of conditions: the beds are going up, and they will be filled with imported machines unless localisation intervenes.
The build-out is best understood as the correction of a capacity deficit rather than as expansion from adequacy. Hospital beds stand at only 1.2 to 2.2 per 1,000 population across the six states, Saudi Arabia highest at about 2.2 and Qatar lowest at about 1.2 (World Bank, 2017 to 2021). That is well below developed-market levels and inconsistent with the region's spending power. The programme behind the correction is quantified in Saudi Arabia at about $65 billion of healthcare transformation.
The installed base on which that programme builds is already substantial in the UAE, which operates more than 150 hospitals and over 5,000 health facilities. Each new facility converts into orders in the categories where import dependence is highest, imaging above all, which is capital-intensive and near-totally imported. The device consequence of the build-out is therefore an increase in the import bill in the short term, whatever the localisation policy achieves later.
The build-out is also institutional, and that part is less visible than the construction. Saudi Arabia has transferred ministry assets to a Health Holding Company and reorganised delivery into 21 integrated health clusters, which changes the identity and the number of counterparties a supplier
must serve. A maker that has sold to a ministry is not thereby qualified to sell to a cluster.
The build-out’s flagships are medical cities, and a deliberate shift from state to private delivery.
The build-out’s most visible form is the medical city, and its most consequential trend is privatisation. Saudi Arabia leads. Under Vision 2030, the kingdom plans to privatise or corporatise some 290 hospitals and around 2,300 health institutions, lifting the private sector’s share of delivery from roughly a quarter toward a third. The Public Investment Fund’s Health Holding Company runs the corporatisation. The flagship King Faisal Specialist Hospital became an independent not-for-profit by royal decree, and new public-private medical cities are rising at Abha, Sakaka and Mecca.
The UAE’s model runs further down the private path: Cleveland Clinic Abu Dhabi, Sheikh Khalifa Medical City and a dense web of private hospitals, many under the Abu Dhabi sovereign health groups, set a template of internationally-branded, privately-operated tertiary care. For medtech this matters twice over. Privatised, internationally-accredited providers buy at the very top of the technology curve, the newest imaging, robotics and digital systems, deepening high-value import demand. And the shift creates new commercial buyers alongside the state, turning the procurement landscape from purely public tenders into a mix of sovereign procurement and corporate purchasing. The medical city is where the Gulf’s wealth, its disease burden and its appetite for the newest technology converge into the densest device demand in the region.
The flagships can be named and dimensioned. King Salman Medical City in Riyadh is planned at more than 1,200 beds, and the NEOM Hospital is designed as a technology-led facility of about 70,000 square metres. The vehicle matters as much as the buildings. Delivery has been reorganised into 21 integrated health clusters, and ministry assets transferred to a Health Holding Company. That is corporatisation under state ownership rather than sale, so the eventual buyer of equipment remains sovereign in substance.
The private tier in the UAE is quantified through its referral traffic. Cleveland Clinic Abu Dhabi, part of M42, recorded a 35 per cent rise in international patient volume during 2024, to more than 10,000 encounters, with patients
arriving chiefly from Kuwait, Saudi Arabia, Pakistan, Bahrain and the United States. Mediclinic operates six hospitals and 29 clinics on international accreditation, and NMC adds further capacity.
The procurement consequence follows directly. Accreditation-grade and medical-tourism demand concentrates in the newest imaging, surgical and digital systems, which is to say in the categories carrying near-total import dependence. Privatisation therefore raises the technology level of Gulf demand faster than it raises the region's ability to supply it, and the medical city is where that divergence is widest. Around 290 hospitals and some 2,300 primary-care centres have been opened to private-sector participation in Saudi Arabia alone, so the number of distinct commercial counterparties is rising faster than the number of beds.
Gulf device regulation has matured fast, and, in tightening, has become a gate that shapes who gets to sell.
Gulf device regulation has professionalised at speed, and the direction is toward stricter, more independent regimes. In Saudi Arabia, the Food and Drug Authority (SFDA) now runs the MDMA2 “Saudi Route” technical-file assessment as the single valid pathway, as of 2026. The old shortcuts that accepted a US or EU approval no longer suffice. The system mirrors the EU’s: four risk classes and rules modelled closely on European medical-device regulation, with timelines running from a few months for low-risk devices to over a year for the highest class. Foreign makers need a Saudi authorised representative.
| Market | Regulator | Pathway | Classes · timeline |
|---|---|---|---|
| Saudi Arabia | SFDA | MDMA2 “Saudi Route” technical file | A–D · ~2–14 months |
| UAE | Emirates Drug Establishment | National registration (from MOHAP) | 4 classes · 5-yr validity |
The UAE has moved the same way, and further. A 2024 federal decree created the Emirates Drug Establishment, which took over the federal health ministry’s regulatory functions through early 2026. It consolidates
oversight under a single national body with a four-class system, local-representative requirements and five-year registration validity. The Gulf-wide trajectory is unmistakable, from light, reference-based oversight toward rigorous, independent, EU-style regimes. For a maker, market access now demands real regulatory investment: a local representative, a technical file, and the patience to clear a maturing but increasingly exacting system. Regulation has become a real gate, and an instrument the sovereign can use to favour those who localise.
The UAE transition should be dated, not described as a process. The dates are on the record. Medical-device marketing authorisations transferred to the Emirates Drug Establishment with effect from 29 December 2025. The establishment assumed 44 core services from the Ministry of Health and Prevention by early 2026 under Federal Decree-Law 38 of 2024. The Department of Health Abu Dhabi and the Dubai Health Authority no longer maintain separate device registries, so a single federal registration now carries a product across all seven emirates. On 24 February 2026 a multiple-authorised-agent mechanism took effect, requiring more than one authorised agent per product.
The other four regimes differ in kind, not merely in rigour. The differences govern entry sequencing. Qatar requires formal registration only of implantable devices, with non-implantables and consumables proceeding on import permits and marketing authorisation, and only a locally registered Qatari representative may file. Kuwait registers all devices and
in-vitro diagnostics under ministerial decrees of September 2022. Bahrain's National Health Regulatory Authority reviews in about six to eight weeks and ties the certificate term, of one to five years, to the quality certificate. Oman operates a notification and listing system recognising FDA, CE and SFDA classifications.
A common spine nonetheless runs through all six: prior clearance in a reference market, a local authorised representative bearing real regulatory liability, a risk classification, and ISO 13485 quality-system compliance.
In a market where the state is the buyer, procurement is policy, and the Gulf’s procurement machinery is formidable.
Because the state buys most of the Gulf’s medical devices, the procurement bodies are where market power and policy concentrate. In Saudi Arabia, NUPCO, the PIF-owned national unified procurement company, runs central buying north of SAR 25 billion a year (around $6.7 billion). That makes it one of the largest single device buyers in the region, and a powerful lever. It has piloted value-based purchasing and grants local makers a price preference. To sell devices into Saudi Arabia at scale is, in large part, to sell to NUPCO.
At the regional level, the Gulf Health Council runs a joint procurement programme across all six states, with total awards of about $813 million in 2023 across more than nine thousand tender items. That pools the buying power of the smaller markets alongside the larger. (The Council publishes award values, not savings, so the $813 million is procurement volume, not a claimed saving.) The point is that Gulf procurement is centralised, large, and increasingly wielded as industrial policy. The same bodies that buy the devices set the local-content preferences designed to make more of them at home. For a maker, NUPCO and the joint buy are not a procurement footnote. They are the core of market access.
One correction matters commercially. The Saudi instrument is a tender weighting, not a price discount. NUPCO embeds a 15 per cent “Made in Saudi” weighting directly into tender scoring, where it is capable of deciding an award, and certain categories carry explicit local-manufacturing or technology-transfer conditions. A weighting of that size operates on the evaluated score rather than on the quoted price, so it cannot be offset by discounting alone, which is the point of designing it that way.
The 2026 rules should likewise be stated at the level the record supports. NUPCO's 2026 procurement rules give priority to products that are both registered with the Saudi Food and Drug Authority and manufactured inside the Kingdom. The company also signed framework agreements during 2026 for the supply and localised production of essential consumables. These cover intravenous sets and syringes, along with gloves and wound care. The defensible formulation is that imported finished product now faces markedly narrower access to awards, rather than that foreign bids are rejected wherever a local alternative exists.
At the regional level the asymmetry with pharmaceuticals is the salient fact. The Gulf Health Council coordinates policy and operates a centralised registration track for medicines, but devices remain national, so the joint buy pools demand without pooling market access. For the four smaller states, whose individual markets sit below roughly $1.1 billion, pooled purchasing is the only mechanism by which they exercise any leverage over price or specification at all.
The consequences compound the localisation problem. A domestic manufacturer cannot easily build to Gulf scale, because its home market is one of six, and four of those six are small; the natural scale economies
that would justify a device plant are split across borders and regulators. The fragmentation also raises the cost of entry for foreign makers, favouring the large multinationals that can absorb six registration processes over smaller or local entrants. It is, in short, a drag on the very industry-building the sovereign funds are chasing: the Gulf wants a domestic medtech base, but its own internal borders keep scale out of reach. Harmonising device registration, as pharmaceuticals already are, would do as much for localisation as any subsidy. That it has not happened is itself a finding.
Six states, six regulators, six registrations: the structural drag on building anything at Gulf scale.
For all its shared wealth and ambition, the Gulf is not one market but six, and for medical devices that fragmentation is a real, under-appreciated constraint. Where pharmaceuticals enjoy a centralised GCC registration procedure, devices do not. Each of the six states demands its own national registration. A maker wanting regional reach must therefore file separately in Saudi Arabia, the UAE, Qatar, Kuwait, Oman and Bahrain, each with its own regulator, timeline and requirements.
The asymmetry is institutional and documented. The Gulf Health Council runs a centralised registration track for pharmaceuticals and none for devices, so a single device may require registration up to six times, against six sets of requirements and timelines. Those timelines are not symmetrical either. The four smaller states typically complete registration in six to nine months, while Bahrain's authority reviews in about six to eight weeks. That makes the sequence in which a maker files a commercial decision rather than an administrative one.
The holding costs compound after approval. Registration validity differs by state, running to five years in Saudi Arabia and the UAE, one to five years in Bahrain tied to the quality certificate, and per certificate in Qatar, Kuwait and Oman. Renewal cycles therefore fall out of alignment and must be managed separately. An authorised representative is mandatory in every state and bears real regulatory liability, which means six relationships, not one.
The scale consequence is arithmetical. Four of the six national markets sit below roughly $1.1 billion, and the largest device-basis market is about $2.34 billion. No single home market in the Gulf is therefore large enough to justify a high-value device plant on domestic demand alone. Harmonisation would create the scale that no subsidy can.
The hardest device-specific localisation targets are weakly sourced, and the caveat matters. Much-repeated figures of “15% medical devices” or “90%-to-25% import reduction” trace to commercial blogs rather than
official policy, and should be treated with caution. What is firmly established is the mechanism. The Gulf uses its procurement power and market access to compel localisation, rewarding those who build, headquarter and manufacture locally and penalising those who only import. The strategy is coercion through purchasing, and it is reshaping how every serious player now approaches the region.
The Gulf is not asking the market to localise. It is compelling it: through a specific stack of mandates.
The Gulf’s localisation strategy is distinctive because it does not lean on incentives alone; it compels, using the state’s position as buyer. Saudi Arabia’s toolkit is the most developed, and its levers stack:
The quantified Saudi target should be corrected and attributed. Vision 2030 sets localisation of 80 per cent of pharmaceutical production by 2030, not 40 per cent, with device ambition stated alongside it rather than given a number. That distinction is worth preserving: the firm target belongs to medicines, while the device-specific figures in circulation remain weakly sourced and should continue to be flagged as such wherever they are repeated.
The UAE pursues the same end through different instruments, and the difference is structural rather than cosmetic. Access is organised through
free zones, principally Dubai Healthcare City and Dubai Science Park, which host light manufacturing and distribution, while the sovereign-backed M42 and PureHealth platforms concentrate buying and partnership. There is no comparable procurement mandate. The Emirati lever is the anchoring of demand; the Saudi lever is the conditioning of supply.
Sovereign manufacturing is the third lever, and its current form is pharmaceutical. The Public Investment Fund established Lifera in 2023 as a commercial-scale contract development and manufacturing organisation, anchoring a domestic production base from which extension toward devices is expected rather than achieved. Across the region the consequence is consistent. Market access increasingly requires a local manufacturing or partnership footprint, not merely a distributor. Entry planning should therefore assume that the footprint, not the price, is the variable on which an award turns in the Kingdom, and that no equivalent requirement applies in the Emirates.
Behind the ambition sits a practical bottleneck: getting a device approved, in a regime that tightens as it matures.
The localisation levers and the demand are real, but so is the friction of getting a device to market, and it is rising as the regimes mature.
Saudi Arabia’s shift to the MDMA2 technical-file route ends the acceptance of reference-market shortcuts. A maker can no longer wave a US or EU approval and expect a quick clearance. It has to compile a full technical file and clear the SFDA’s own assessment, with timelines stretching past a year for high-risk devices. The UAE’s consolidation under the Emirates Drug Establishment imposes a parallel discipline. The SFDA has even issued specific guidance for artificial-intelligence and machine-learning devices, a signal that the frontier categories will be regulated, not waved through.
For makers, the registration reality reshapes strategy two ways. It raises the cost and lead time of entry, favouring well-resourced incumbents and anyone willing to invest in local regulatory capability, which dovetails neatly with the localisation agenda. And it turns the local authorised representative, the technical file and the regulatory relationship into strategic assets rather than administrative chores. The Gulf is no longer a market a foreign maker can serve at arm’s length through a distributor and a foreign approval. It increasingly demands a genuine local presence, precisely the outcome the localisation policy intends. Regulation and industrial policy are pulling the same way.
A renewal cliff is now in prospect and should be planned for. Saudi marketing authorisations are reported to run for up to three years, so the first wave of Class A authorisations, filed ahead of the SAUDI-DI unique-device-identification mandate of 1 September 2024, falls due for renewal
from about September 2027. The figure comes from trade-press analysis published in 2026 and should be verified against the SFDA Implementing Regulation before it is relied upon commercially.
The Saudi obligation is also wider than registration itself. Market access requires a Medical Device Marketing Authorisation together with an establishment licence, valid five years, filed through the GHAD portal. It carries continuing post-market duties too: safety reporting, unique device identification and lifecycle management, with NUPCO prequalification additionally required for public sales. Entry is therefore a standing compliance function rather than a project with an end date.
The UAE regime imposes a parallel discipline on a single portal. Product registration and renewal run through the Emirates Drug Establishment, as do variations, import permits, pharmacovigilance and post-market compliance. Validity is five years, with a requirement for more than one authorised agent per product. Facility licensing remains with the Department of Health in Abu Dhabi and the Dubai Health Authority. Both regimes now place the authorised representative, the technical file and the regulatory relationship among a maker's strategic assets, since none of the three can be assembled at short notice once a tender is in the market.
What makes Gulf medtech unlike any other market is who is funding its transformation: the state’s own wealth funds.
The one feature that separates Gulf medtech from every other emerging market is sovereign capital. The transformation of the sector is being driven not by venture capital or private enterprise but by the region’s sovereign wealth funds. Those are Saudi Arabia’s Public Investment Fund, Abu Dhabi’s Mubadala and ADQ, and Qatar’s QIA, deploying state wealth at a scale and with a patience no private investor can match. These funds do more than finance healthcare. They build national champions, found manufacturers, and use their portfolio companies as instruments of industrial policy.
That rewrites the strategic logic. In a normal market, localisation depends on whether private firms find it profitable to manufacture locally. In the Gulf, the sovereign can simply decide to build the capability and fund it through the cycle, swallowing years of loss for a strategic goal. The funds can also pair capital with the state’s own purchasing power, a PIF-owned manufacturer selling to PIF-owned NUPCO, closing the loop between investment and demand. The result is a localisation effort with resources and coordination unavailable anywhere else. Whether sovereign capital
can manufacture capability as readily as it manufactures facilities is the open question. That it is the defining force is not in doubt.
The roster is wider than the four funds usually named, and the breadth matters because it multiplies the points of entry. Alongside the Public Investment Fund, Mubadala, ADQ and the Qatar Investment Authority sit the Abu Dhabi Investment Authority, with global healthcare and life-sciences allocations, and the Investment Corporation of Dubai. So do the Kuwait Investment Authority, which is the world's oldest sovereign fund, Bahrain's Mumtalakat at about $17.6 billion of assets under management, and the Oman Investment Authority. Combined Gulf sovereign assets of roughly $5 trillion are expected to approach $18 trillion by 2050.
The distinguishing behaviour is construction rather than allocation. The Public Investment Fund created Lifera as a contract manufacturer in order to localise production. Mubadala and G42 created M42 to fuse care delivery with applied artificial intelligence. Mubadala and the Qatar Investment Authority have together backed device makers directly, including the wearable company WHOOP. For a medtech business the funds are
therefore simultaneously the largest potential partner, the route to localisation and the most consequential acquirer.
A thinner layer of conventional capital sits above the sovereign one, and it is increasingly institutionalised. Saudi Arabia has committed some $3.24 billion to health venture and strategic funds. Sanabil has partnered Redesign Health to build a venture studio targeting at least 20 healthcare companies in the Kingdom. The 2025 Global Health Exhibition in Riyadh alone surfaced more than $33 billion in announced strategic health investment.
The progress is real but early, and the honest figures matter. Saudi Arabia now hosts around 150 licensed medical-device factories with roughly SAR 3.1 billion of investment. That is a genuine base. It is concentrated in
lower-value products, though, and holds only about 6% of the domestic market. The localisation is driven through Vision 2030’s health transformation, the regional-headquarters rule, NUPCO’s procurement preferences and the local-content programme, all pointing the same way. Saudi Arabia has the clearest mandate, the deepest capital and the most coordinated machinery in the Gulf. The open question is whether that machinery can climb the value curve, from making syringes to making scanners, or whether it localises assembly and headquarters while the deep technology stays abroad.
The kingdom is the Gulf’s most aggressive localiser, deepest pockets, clearest mandate, hardest problem.
Saudi Arabia is the Gulf’s most determined localiser, and the Public Investment Fund is its instrument. In June 2023 the PIF launched Lifera, a commercial-scale contract development and manufacturing organisation targeting insulins, vaccines, plasma products and advanced therapies. It also took a majority of SaudiBio, and has since signed manufacturing agreements with global pharma names. Alongside it, the kingdom launched a National Biotechnology Strategy in January 2024, targeting tens of billions in non-oil GDP and tens of thousands of jobs by 2040. The
ambition is large. It is to build, from a near-zero base, a domestic life-sciences and medical-manufacturing industry.
The kingdom's scale and its growth rate point in opposite directions. A population of roughly 37 million supports the region's largest device market at about $2.34 billion in 2024. That is forecast to reach approximately $4.45 billion by 2035 at around 6 per cent a year, the slowest compound rate of the six states despite the largest base. Growth leadership sits with the smaller markets, so the Saudi case for localisation rests on absolute volume rather than on momentum.
The digital adjacency is growing considerably faster than the device market and is being funded accordingly. The Saudi digital-health market is projected to rise from about $4.4 billion in 2024 toward $15.3 billion by 2033. The institutional scaffolding has been built to match, including the Sanabil and Redesign Health venture studio and a national commitment of some $3.24 billion to health venture and strategic funds. Where the kingdom is building capability quickly, it is building it in software.
Access to the device market remains mediated. The high-value segment is held by the multinationals and reached through established distributors, principally Tamer Group, Banaja, Cigalah and Al Faisaliah Medical Systems, which hold the registrations and the tender relationships. The unambiguous entry sequence is SFDA registration, NUPCO prequalification, and a local manufacturing or technology-transfer footprint sufficient to reach the localisation-weighted tenders.
Where Saudi Arabia builds a manufacturer, Abu Dhabi has built an integrated health-industrial complex.
The UAE’s approach, centred on Abu Dhabi, is to build an integrated health-industrial complex rather than a single manufacturer. Since 2024 the emirate has organised its strategy around a triad of sovereign-backed groups. There is PureHealth, the region’s largest healthcare platform, covering care delivery and insurance under ADQ; Arcera, an ADQ pharmaceutical venture; and M42, the Mubadala-and-G42 tech-enabled
provider that fuses healthcare with artificial intelligence. Between them they span provision, pharma, insurance and health technology, backed by some of the largest sovereign investors on earth.
The UAE pairs the triad with life-sciences infrastructure built to draw industry in. There is Dubai Science Park, home to hundreds of companies, and Masdar City’s life-sciences cluster, which opened the Gulf’s first commercially-scaled shared laboratory in 2025 with M42. The emphasis is on becoming a regional hub, for research, for tech-enabled care, for the headquarters and operations of global firms, rather than a low-cost factory. The bet is that connectivity, capital and regulatory sophistication can capture the high-value, knowledge-intensive end of medtech (AI, diagnostics, advanced therapies, data) even if the UAE never makes a commodity device. It is a different localisation thesis from Saudi Arabia’s, hub over factory.
The commercial case for the hub model is visible in the growth rate. The UAE device market is put at about $3.8 billion in 2024, rising to approximately $6.3 billion by 2030 at around 8.9 per cent a year, against roughly 6
per cent in Saudi Arabia. Dubai's healthcare sector alone earns more than $4.6 billion annually. That is achieved on a population of about 11 million, which is to say on per-head demand that no Gulf state other than Qatar matches.
The access infrastructure is deliberately light. Free zones, principally Dubai Healthcare City and Dubai Science Park, host light manufacturing and distribution rather than heavy plant, and the market is supplied through distributors such as Gulf Drug and Al Zahrawi Medical. Nothing in the Emirati regime corresponds to a procurement weighting: demand is anchored through the sovereign platforms instead, and supply is left to arrange itself.
The chosen category is the only one in the eight-category framework that is not import-gated. Software as a medical device and artificial intelligence is gated by talent and data rather than by manufacturing, and the UAE is the only state of the six rated high on it. The hub thesis is therefore not a softer version of the Saudi thesis but a bet on the single category where the Gulf's manufacturing deficit does not apply.
Kuwait, Oman and Bahrain have thinner medtech stories, their markets too small to anchor domestic manufacturing and their data sparse. Their realistic role is as buyers and, through the Gulf Health Council’s joint procurement, as participants in pooled regional purchasing rather than producers. The lesson of the smaller states is the fragmentation problem in human form. Each is too small alone to justify a device industry, and the absence
of a unified market keeps them from combining into one. For them the localisation question is largely moot. They will import, and their leverage lies in collective procurement and in specialised, high-value niches like Qatar’s, where sovereign wealth can buy a place at the frontier of medicine without ever manufacturing at scale.
Beyond the two giants, four smaller states chase focused, high-value niches rather than scale.
Beyond Saudi Arabia and the UAE, the Gulf’s smaller states cannot chase scale, so the ambitious ones chase focus. Qatar, backed by the Qatar Investment Authority’s vast resources, has concentrated on high-value, specialised medicine. Sidra Medicine set up the country’s first gene-therapy centre, among the first handful in the world to administer a leading gene therapy, and the QIA has steered billions into health and biotech projects. Qatar is repeatedly cited as the Gulf’s fastest-growing national device market, a function of intense per-capita spending on a small, wealthy population.
One widely repeated characterisation does not survive the reconciled basis. Qatar is sized at about $0.69 billion in 2024 rising to roughly $0.98 billion by 2029, a compound rate near 7.2 per cent, which places it fourth
of the six on growth. Bahrain leads at about 9.2 per cent from the smallest base of around $0.4 billion, followed by the UAE at about 8.9 per cent. Saudi Arabia is slowest at about 6 per cent. Qatar is the Gulf's most advanced small market. It is not its fastest-growing one.
Qatar's distinction is in the sophistication of its provision rather than in its rate of expansion. Hamad Medical Corporation operates twelve hospitals as the dominant public network. Sidra Medicine, opened in 2018 as a fully digital, paperless women's and children's hospital on an Epic record system, serves as a regional referral hub. The Primary Health Care Corporation handles community care, and the Qatar Genome Programme has sequenced more than 6,000 whole genomes. The National Health Strategy 2024 to 2030 prioritises digital transformation and infrastructure.
The other three are distinct propositions rather than a residual. Kuwait, at about $0.74 billion in 2025 rising toward $1.31 billion by 2033, carries the heaviest disease burden and anchors it on the Dasman Diabetes Institute, a centre of excellence recognised by the International Diabetes Federation. Bahrain offers the fastest first registration in the Gulf. Oman, at roughly $0.8 to $1.1 billion, is building through the Royal Hospital, Sultan Qaboos University Hospital and the Sultan Qaboos Comprehensive Cancer Centre.
PureHealth matters to this read as both a demonstration and a caveat. The demonstration is that sovereign capital can assemble, fast, a profitable, internationally-expanding healthcare champion, integrating the demand side at a scale and speed private capital could not match. That means the hospitals and the insurance, and the patient relationship with them. The caveat
is that PureHealth is a provider and platform, not a device manufacturer. It embodies the Gulf’s strength in buying, integrating and operating healthcare, not in making the devices that healthcare runs on. It is the import side of the thesis, superbly executed. The question it poses is whether the same sovereign model that built a buyer of the first rank can build a maker of one, which is the harder problem by far.
No company embodies the sovereign-built health platform more completely than Abu Dhabi’s PureHealth.
PureHealth is the clearest example of what sovereign capital can build in Gulf healthcare. Backed by ADQ, it has become the Middle East’s largest healthcare platform in a handful of years. It spans hospitals and diagnostics, along with insurance and health technology. Its December 2023 IPO raised about $986 million. The FY2024 results were striking, with revenue of around AED 25.8 billion, up 58%, and net profit of roughly AED 1.7 billion, up 78%. It has expanded internationally, buying the UK’s Circle Health for about $1.2 billion and taking a US footprint through Ardent Health.
The platform's function within the localisation architecture is specific, and it is not manufacturing. In the Emirati model the sovereign-backed platforms, PureHealth alongside M42, serve as demand anchors: they concentrate buying and partnership in place of the procurement mandates Saudi Arabia uses. The instrument is therefore the aggregation of purchasing rather than the conditioning of supply, which is consistent with a jurisdiction that has chosen not to legislate local content for devices.
The buyer landscape it sits within is dense and institutional. Demand in the UAE concentrates in SEHA and the Department of Health in Abu Dhabi, the Dubai Health Authority at facility level, and private groups including Mediclinic and NMC, with procurement in Abu Dhabi running through SEHA's vendor-qualification processes. Access to all of them is mediated by distributors holding the registrations and tender relationships, so an integrated platform does not remove the intermediary layer.
The caveat the chapter draws can be put in the framework's own terms. The categories such a platform buys in greatest volume, imaging and implants, carry near-total and very high import dependence respectively. A sovereign buyer of the first rank therefore enlarges the import bill as it grows, and does so in precisely the categories localisation policy finds hardest to reach. The demonstration and the caveat are both real. They are the same fact seen from two sides. Sovereign capital has proved it can build a buyer of international scale considerably faster than it can build a supplier of any scale.
The Gulf’s most distinctive bet fuses sovereign capital, healthcare and frontier artificial intelligence.
If PureHealth shows the Gulf buying and operating healthcare at scale, M42 shows it reaching for the technology frontier. Formed in 2023 from the merger of G42 Healthcare and Mubadala Health, M42 runs more than 480 facilities across 26 countries and pairs care delivery with serious AI muscle. Its Med42 clinical large language model was trained on G42’s Condor Galaxy supercomputers, among the most powerful AI systems in the world. It has grown by acquisition, taking Sweden’s Diaverum to build a global dialysis network, a direct play on the Gulf’s renal-disease burden.
M42 embodies the UAE’s distinctive localisation thesis, that the Gulf can leapfrog commodity manufacturing and capture the high-value, knowledge-intensive layer of medtech. That layer is AI diagnostics and clinical software, together with data-driven care. This is the one part of the stack where the Gulf’s strengths (capital and compute, data and ambition) line up with the opportunity, and where it might genuinely lead rather than import. The strategy sidesteps the manufacturing problem entirely. Software and AI scale without factories, and the Gulf’s sovereign compute and capital rank with any. The catch is that the AI rides on imported hardware. The scanner is still foreign even when the algorithm reading it is Emirati. M42 is
the Gulf’s most credible claim to building, not just buying, advanced medical technology, at the software layer, if not yet the hardware.
One figure should be reconciled to the internal basis. M42 is recorded at more than 450 facilities across 26 countries, formed in 2023 from the merger of G42 Healthcare and Mubadala Health; where a higher facility count appears it should be restated to that figure or sourced separately. The scale is not in question, but the number in circulation has drifted and the lower, documented count is the one to publish.
The data layer around M42 is what makes the software thesis credible, and it is largely public infrastructure. Abu Dhabi's health-information exchange, Malaffi, is operated by Abu Dhabi Health Data Services with M42. NABIDH in Dubai held 10.4 million records across 1,888 facilities by mid-2025, and Riayati covers the northern emirates and the national unified record across roughly 5,000 facilities. Taken together the three exchanges make on the order of 1.9 billion records accessible. The Emirati Genome Programme, backed by G42 Healthcare, sits alongside them.
The constraint on that thesis is the same fragmentation that gates manufacturing. Each state operates its own data-sovereignty and privacy framework, so cross-border genomic and clinical collaboration within the Gulf remains limited. A model trained on one national population cannot straightforwardly be improved on the other five, which caps the regional advantage that scale in data was supposed to confer.
The real test of the localisation strategy is the one group that matters most: the global firms that actually make the devices.
The ultimate test of the strategy is whether it changes the behaviour of the multinationals that make the devices, and it does. The global leaders that dominate Gulf medtech (Medtronic, GE HealthCare, Siemens Healthineers, Philips, Abbott, BD, Johnson & Johnson MedTech) are responding to the regional-headquarters rule and the procurement
preferences by deepening their Gulf footprint. GE HealthCare moved its regional headquarters to Riyadh and built Saudi service centres. Siemens Healthineers opened a Riyadh regional HQ and a joint innovation centre with the Saudi health ministry, and Abbott set up a Riyadh HQ. Johnson & Johnson MedTech launched direct Saudi operations. BD is pursuing local manufacturing and an AI partnership with the ministry.
| Multinational | Gulf localisation move |
|---|---|
| GE HealthCare | Regional HQ relocated to Riyadh; 3 service centres |
| Siemens Healthineers | Riyadh RHQ + innovation centre with MoH |
| Abbott | Riyadh RHQ (2023); decade of local manufacturing |
| J&J MedTech | Direct Saudi operations launched (2024) |
The pattern is real but partial, and the distinction is the whole point. The multinationals are localising headquarters and service, and distribution too, drawn by access to the region’s procurement. Here and there they localise assembly. But they are not, for the most part, relocating the deep manufacturing and R&D that create high-value devices. The levers are strong enough to pull the global firms onshore in their commercial and service operations, securing jobs and presence. They have not yet been strong enough to move the core of the industry, the factories and laboratories where scanners and implants are designed and built. Whether they can is the crux of the localisation gap.
The supplier field is wider than the firms named above, and each occupies a defined position. Alongside Medtronic, GE HealthCare, Siemens Healthineers, Philips, Abbott, Becton Dickinson and Johnson & Johnson MedTech, the regional majors include Stryker in orthopaedics, surgical and neurotechnology. They also include Boston Scientific in interventional cardiology and endoscopy, and Roche Diagnostics in in-vitro diagnostics and laboratory, where demand is driven directly by the diabetes burden. Between them they hold the high-value segment across all six states.
Access, however, is mediated rather than direct, and that is the part localisation policy has not changed. Registrations and tender relationships are held by established distributors: Gulf Drug, the Zahrawi Group, Metromed, Advanced Medical Equipment and Gulf Medical Company across the Emirates and the wider region. For a manufacturer without a local entity, the distributor remains the gatekeeper to both registration and procurement, so a regional headquarters does not by itself displace the intermediary.
The localisation pressure also lands unevenly by category. It bites where import dependence is moderate and the technology barrier low, in consumables, disposables and point-of-care diagnostics, and it has least purchase where dependence is near-total, in imaging and implants. The observed pattern of onshoring is therefore not a matter of corporate willingness so much as of where onshoring is technically feasible at all.
Strip away the ambition and the announcements: what does the Gulf actually make? Less than the rhetoric implies.
Beneath the rhetoric the output is thin, and the gap between announcement and production is wide. Saudi Arabia’s roughly 150 licensed device factories and SAR 3.1 billion of investment are real, but they hold only about 6% of the domestic market and cluster in low-value products, the bandages, gloves and syringes the official literature candidly names. Across the Gulf, local pharmaceutical and device production combined does not exceed around 10% of consumption. The UAE’s domestic production runs to disposables and spare parts, and one notable joint venture makes auto-disable syringes at volume. The venture is genuine. It sits firmly at the commodity end.
The research for this read turned up no discrete, named, net-new high-value device-manufacturing plant announced for 2024 to 2026 in the primary record. There are only aggregate market figures and headquarters relocations. That absence is itself a finding. The Gulf is localising procurement, headquarters, assembly and the commodity end, but the announcement of a plant making, say, MRI machines or cardiac implants at scale has not yet come. The manufacturing reality is plain. The Gulf today makes the cheap, high-volume, low-margin devices and imports
everything that needs deep technology, precision engineering or accumulated IP. Localisation has begun at the bottom of the value curve. Whether it climbs is the open question.
The region's sovereign manufacturing vehicle is pharmaceutical, and the distinction should be made plainly. Lifera, established by the Public Investment Fund in 2023, is a commercial-scale contract development and manufacturing organisation for biopharmaceuticals, with extension toward devices expected rather than delivered. In the internal record of the region's players, the entire local-manufacturing layer is listed as Lifera together with emerging consumables makers, which is an accurate description of its present depth.
The expected trajectory is explicit and it is slow. Consumables and disposables localise first, since the technology barrier is low. Imaging, implants and advanced diagnostics are expected to remain import-reliant well beyond 2030, because the capability gap is wide. Software and artificial intelligence may leapfrog hardware altogether, since they play to capital and ambition rather than to a manufacturing base. The binding constraints are capability and scale, not capital or will.
The scale constraint points to a single resolution. Since four of the six markets sit below roughly $1.1 billion and the largest device-basis market is about $2.34 billion, a high-value plant in the Gulf can only be justified against demand beyond the Gulf. An export base serving the wider Middle East and North Africa is therefore not an additional ambition but the precondition for the manufacturing ambition itself.
The Gulf’s best chance to lead, not import, sits one layer up from the device: in software and AI.
The Gulf cannot yet make the hardware. It is making serious moves in the software and intelligence that ride on top of it, and this is its most credible path to leadership rather than dependence. Saudi Arabia’s Seha Virtual Hospital, recognised as the world’s largest, links hundreds of facilities and serves close to half a million patients a year, deploying AI for imaging and for breast-cancer and diabetic-retinopathy screening. The kingdom’s data-and-AI authority has earmarked large sums for health IT and partnered with global technology firms. The Saudi AI-in-healthcare market is projected to grow several-fold by 2030. The UAE’s M42, with its Med42 model and sovereign compute, is building at the same frontier.
The digital and AI layer plays to the Gulf’s genuine strengths rather than to its weakness in precision manufacturing. Those strengths are capital and
compute, data and the centralised authority to deploy systems nationwide. A virtual hospital or a clinical AI model scales without a factory and runs on imported hardware. It attacks the region’s real constraint, which is not a shortage of machines but a shortage of clinicians to use them, a shortage AI multiplies. The Gulf may never make the world’s scanners, but it can plausibly lead the world in deploying AI across them at population scale. The adjacency is where import dependence matters least and the Gulf’s advantages matter most.
The flagship figure requires correction, and the corrected version is more impressive than the loose one. Seha Virtual Hospital connects 241 hospitals and more than 1,400 health centres, per the Saudi Ministry of Health on 9 August 2026, superseding both the earlier counts of 224 and 242 facilities and the looser description of hundreds of sites. It holds a Guinness World Record as the world's largest virtual hospital, and its reported artificial-intelligence triage accuracy runs up to 95 per cent, alongside augmented-reality surgical guidance and digital twins.
The national digital layer behind it is broader than the virtual hospital alone. Saudi Arabia operates the Sehhaty, Mawid and Seha applications and the 937 service as citizen front-ends. Oman runs its home-grown Al Shifa ministry record, and Bahrain runs I-SEHA as its national health information system. The hospital tier is held largely by Oracle Health, formerly Cerner, with Epic at Cleveland Clinic Abu Dhabi and Sidra Medicine. The exchanges above them are state-built, which is why national deployment is achievable at a pace no private market matches.
At the frontier the pattern repeats. During 2026 Aramco and Pasqal inaugurated Saudi Arabia's first quantum computer and the Middle East's first commercial quantum-computing-as-a-service platform, with a separate Aramco and IBM quantum innovation hub alongside. The healthcare relevance is prospective, expected first in drug discovery, molecular simulation and optimisation, with quantum sensing a longer-term route to less invasive diagnostics.
What the deal flow conspicuously lacks is large, named investment in high-value domestic device manufacturing. The money builds hospitals and buys provider networks abroad. It founds pharma and biotech ventures and acquires dialysis and diagnostics businesses, but it has not yet produced the flagship Gulf device manufacturer making advanced
equipment at scale. That is the thesis confirmed in capital allocation. Sovereign wealth is superb at building the demand side and the service side of healthcare, and at buying capability abroad, but it has not yet cracked domestic high-value device-making. For an investor, the move is to follow the sovereign. The deals will be in platforms, AI, pharma and international assets. Any genuine high-value device-manufacturing announcement should be read as the signal that localisation has finally reached the part that matters most.
The deal flow confirms the thesis: sovereign money building and buying healthcare platforms, not device factories.
The transactions of recent years tell the localisation story in deals, and the pattern is consistent. The headline activity is sovereign-backed platform building and international acquisition. There is PureHealth’s near-billion-dollar IPO and its $1.2 billion purchase of Circle Health, M42’s formation and its acquisition of Diaverum, the PIF’s launch of Lifera and purchase of SaudiBio, and the QIA’s multi-billion health commitments. The capital deployed is vast, patient and strategic, exactly the profile sovereign wealth provides, and it pools in provision, platforms, pharma manufacturing and international expansion.
The deal record can be stated precisely, and its composition is the finding. Of roughly 400 Gulf healthcare transactions recorded between 2021 and April 2025, the UAE accounted for 198 and Saudi Arabia for 170, leaving about 32 across Qatar, Kuwait, Bahrain and Oman together. Much of that activity is strategic or sovereign-linked rather than classic early-stage venture, so the count measures corporate and state consolidation more than it measures a funding pipeline.
Where independent venture capital does appear, it is almost entirely digital rather than device. The visible names are Okadoc in teleconsultation and booking, with about $22.3 million raised and expansion into Saudi Arabia, and Klaim, an insurance-claims platform for providers, at $26 million in a 2025 Series A round. Alma Health sits in virtual chronic care at $10 million.
Sehteq has grown past 700,000 insurance customers, Cura has more than 350,000 users and 4,500 doctors, and Nuxera AI took $2.5 million pre-seed in 2025. The institutional scaffolding has followed, including Abu Dhabi's Hub71+ Life Sciences accelerator.
The absence is therefore consistent across both layers of capital. Neither the sovereign funds nor the venture market has financed a high-value domestic device manufacturer, and the money that is moving is moving into provision, platforms, insurance adjacencies and software. For an investor the practical consequence is that the announcement to watch for is a named high-value device plant, since nothing in the recorded deal flow to April 2025 constitutes one.
The Gulf is running two different localisation experiments at once, and the contrast is the strategic lesson.
The Gulf’s two largest markets are pursuing genuinely different localisation models, and the contrast clarifies the whole question. Saudi Arabia’s model is the factory. Build a domestic manufacturing base from the ground up, compel it through procurement preferences and the regional-headquarters rule, and aim eventually to climb from commodity devices toward high-value ones. It is the more ambitious bet, with the deeper capital and the larger home market. It is also the harder problem, because it means building manufacturing capability the kingdom has never had.
| Model | Saudi Arabia: the factory | UAE: the hub |
|---|---|---|
| Bet | Build domestic manufacturing | Capture the high-value / AI layer |
| Levers | RHQ rule, NUPCO preference, local content | Connectivity, capital, regulation |
| Risk | Capability it never had | No traditional device industry |
The UAE’s model is the hub. Do not chase commodity devices, but capture the high-value, knowledge-intensive layer, and with it the regional
headquarters and operations of global firms, on the strength of connectivity, capital and regulatory sophistication. That layer means AI and diagnostics, along with advanced therapies and research. It is the more realistic bet about where a small, open economy can add value, and the less likely to yield a traditional device industry. Neither is obviously right. They are wagers on different theories of how a wealthy, import-dependent region builds advantage. The likely outcome is that both succeed partially and differently. Saudi Arabia localises the lower and middle of the value curve and the commercial presence of the multinationals, while the UAE captures the digital, AI and hub layer, and the deepest device technology stays, for years yet, imported by both.
The two models can be separated by instrument, which is the cleanest way to compare them. Saudi Arabia operates procurement scoring, technology-transfer conditions on certain categories, sovereign manufacturing through Lifera and a quantified localisation target for pharmaceuticals of 80 per cent by 2030. The UAE operates free zones for light manufacturing and distribution and sovereign demand anchors in M42 and PureHealth, and sets no comparable mandate. One jurisdiction conditions supply; the other aggregates demand.
The underlying arithmetic differs as sharply as the instruments. Saudi Arabia holds a population of roughly 37 million, the largest spend and the slowest growth rate of the six at about 6 per cent a year. The UAE holds about 11 million people and grows at about 8.9 per cent on a broader
reported basis. The kingdom's case rests on volume sufficient to justify a plant; the Emirati case rests on intensity sufficient to justify a hub.
On the internal demand matrix, which is a qualitative judgement rather than a measurement, the division is already visible. The UAE is the only state of the six rated high on software as a medical device and artificial intelligence, and the only one rated high in the ophthalmic, dental and related group, reflecting medical tourism. Saudi Arabia is rated high across six of the eight categories, which is a statement about breadth of demand rather than about capability to supply it.
The defining tension of Gulf medtech is the distance between sovereign ambition and industrial reality.
The tension this read keeps returning to is the gap between the Gulf’s localisation ambition and its industrial base. The ambition is genuine, funded and coordinated as nowhere else, resting on sovereign capital, procurement mandates, regional-HQ rules and national strategies all aimed at a domestic medtech industry. The reality is that the base it must be built from is tiny. There is around 6% local share in Saudi Arabia, concentrated in commodities, and near-total import dependence elsewhere. There is no flagship high-value device manufacturer, and, in the primary
record, an absence of the plant announcements that would signal a real climb up the value curve.
What the evidence suggests is that sovereign capital can compel some things and not others. It can compel headquarters, commercial presence, assembly and commodity manufacturing, the multinationals are visibly responding. It can build first-rate buyers, platforms and AI capability, PureHealth and M42 prove it. What it has not yet shown it can do is conjure, against a thin industrial base and six fragmented markets, the deep manufacturing and engineering capability that high-value devices require: the accumulated know-how that took the US and Germany decades. Sovereign will is necessary; it may not be sufficient. The localisation gap is the difference between deciding to have an industry and actually building one, and it is the question on which the next phase of Gulf medtech turns.
The gap has a shape that policy cannot easily reverse, and the shape is an inversion. The localisation opportunity runs opposite to the value chain. The easiest wins sit in the low-technology, high-volume categories, consumables and point-of-care diagnostics. The categories the region most
wants to make at home, imaging and implants, carry near-total and very high import dependence and are the hardest to localise. Policy therefore acquires the least valuable capability first, and does so by design rather than by failure.
The obstacles are named in the kingdom's own assessment, which is unusually candid. They are a skilled high-technology manufacturing talent gap, localisation mandates that raise the cost of entry, execution risk across the giga-projects, continuing dependence on imported components and intellectual property, and intense competition for NUPCO tenders. Not one of those is a capital constraint, which is consistent with the conclusion that the binding constraints are capability and scale.
The Emirati route does not close the same gap, and should not be read as though it did. Its object is the localisation of headquarters, research, data and tech-enabled care, not of manufacture. On the region's own eight-category framework, therefore, the gap closes at present only in the one category that was never import-gated to begin with.
This matters because manufacturing capability is, in the end, embodied in people, not just facilities. A sovereign fund can build a factory. Staffing it with the engineers, quality specialists and scientists who can make high-value devices, and keeping them, is slower and harder than deploying capital. The Gulf’s heavy reliance on imported labour also leaves its health system and any nascent industry exposed to the mobility of that workforce. Localising devices therefore depends on localising talent, on
building the domestic scientific and engineering base that no procurement preference can shortcut. It is the deepest of the constraints, and the slowest to resolve.
Beneath the capital lies a harder limit: a healthcare system, and an industry, run largely by people from elsewhere.
The constraint sovereign capital cannot quickly buy past is people. Gulf healthcare runs overwhelmingly on an expatriate workforce. In the UAE, expatriates make up an estimated 82% of physicians and 96% of nurses, and in Saudi Arabia around 90% of the private-sector health workforce. Physician and nurse density across the Gulf sits below OECD levels, and Saudi Arabia alone is reckoned to need tens of thousands more doctors by 2030. A medical-technology industry must design, manufacture, regulate and service devices. It needs a depth of specialised engineering, scientific and clinical talent the region does not yet have and currently imports along with the devices.
The shortage is measurable before any question of nationality arises. Physician density across the six states runs from about 1.0 per 1,000 population in Bahrain to roughly 3.1 in Saudi Arabia, and hospital beds from about 1.2 to 2.2 per 1,000 (World Bank, 2017 to 2021). Both sit below developed-market norms in states whose spending power is at or above them, so the clinical workforce is a constraint on the use of devices even where the devices themselves are affordable.
The constraint extends into the regulatory and quality professions, which is less often noticed. An authorised representative is mandatory in all six states and bears real regulatory liability, and in Qatar and Bahrain only a locally registered representative may file at all, while ISO 13485 quality-system competence is expected throughout. Localising manufacture therefore requires not only engineers but a domestic cadre of regulatory affairs and quality specialists, a profession that scarcely exists in a market built on distribution.
The region's chosen frontier is the one most exposed to this constraint. Software as a medical device and artificial intelligence is gated by talent and data rather than by manufacturing. The institutions built around it are therefore properly read as talent instruments as much as technology
ones. Those are the Qatar Genome Programme, the Emirati Genome Programme, Sidra Medicine and Hub71+ Life Sciences.
For a maker or investor, the Gulf is among the most attractive markets in the world, on the sovereign’s terms.
For a device maker, the Gulf offers the richest demand in the world on the most navigable terms: a state payer, a funded build-out, and a clear, if demanding, path to access. The viable strategies are well-defined by the localisation regime. Establish a regional headquarters to win government contracts. Secure SFDA or Emirates Drug Establishment registration through a local representative. Localise assembly or manufacturing to capture procurement preference, or partner a sovereign-backed champion. The Gulf rewards those who commit to a real local presence and penalises those who only ship from abroad.
Three risks could bend the path. Fiscal dependence is the deepest. The whole build-out rests on oil revenue, and with Saudi Arabia’s fiscal break-even creeping up against heavy megaproject spending, a sustained oil-price fall could slow the health expansion. Execution risk is real. The
localisation ambition may outrun the industrial and human base, leaving expensive facilities under-used and targets quietly missed, as some already have been. And the fragmentation could persist, keeping the six markets sub-scale and deterring the domestic manufacturing the region wants. None of this reverses the underlying demand, since the disease burden and the state payer guarantee a large, growing market. But each shapes how fast localisation moves and how much of the value the Gulf captures rather than imports.
The access sequence can be set out as five steps. It is the same five everywhere. First comes clearance in a recognised reference market, typically a United States FDA 510(k) or premarket approval, an EU CE mark, or increasingly an SFDA approval. Second is risk classification from A to D by the national regulator. Third is the appointment of an authorised representative or licensed distributor in-country. Fourth is national registration with the SFDA, the Emirates Drug Establishment, Qatar's Ministry of Public Health, Kuwait's Drug and Food Control, Bahrain's NHRA or Oman's Ministry of Health. Fifth is procurement listing, with NUPCO in Saudi Arabia and the SEHA and Dubai Health Authority processes in the UAE.
Bahrain repays being treated as a deliberate first filing rather than as a small market. Its regulator reviews in about six to eight weeks against six to nine months in the other smaller states, it is among the region's most transparent, and the kingdom sits a short causeway from the largest market in the Gulf. A low-cost proving ground with a fast certificate is worth
more at the start of a regional programme than its $0.4 billion market would suggest.
To the three risks named above a fourth should be added, and it is analytical rather than commercial. Country market values are drawn from different research houses on incompatible scopes and must not be summed, so the most common error in sizing this region is made before any strategic judgement is reached.
What a maker or investor should expect Gulf medtech to look like by 2028.
Over the next two to three years, Gulf medtech will keep growing hard on its unshakeable demand and localise at the margins where sovereign power can compel it. Four developments look most likely:
The binding question remains the localisation gap. The market’s growth is not in doubt; what is in doubt is whether the Gulf converts its sovereign will into genuine high-value manufacturing capability, or stays the world’s great buyer, localising headquarters, assembly and AI while importing the deep technology. The smart position, for maker and investor alike, is to serve the certain demand while helping the sovereign close the gap, on its terms, at whatever rung of the value curve it is ready to climb.
The fast edges can be named with figures, and both sit outside hardware manufacturing. Wearable health devices are projected to grow from about $1.05 billion toward $3.12 billion by 2032, roughly 17 per cent a year and the fastest segment in the market. The Saudi digital-health market is projected to rise from about $4.4 billion in 2024 toward $15.3 billion by 2033. Neither trajectory depends on a factory. That is why both are more certain than the localisation programme itself.
Two financing reforms fall inside the window and will show up as demand. Bahrain's SEHATI programme and Oman's Dhamani platform, launched by the Financial Services Authority on 1 January 2025, are both still
phasing in. Private-sector demand in the two most publicly funded systems therefore arrives during the forecast period rather than after it. The Emirates Drug Establishment's multiple-agent regime, in force since February 2026, will meanwhile continue to reshape how products are represented in the region's second-largest market.
On the software layer the governance question is also being settled in-region. Qatar, Saudi Arabia and the UAE have been among the global front-runners in framing rules for artificial intelligence in health, rather than waiting for them. The category in which the Gulf genuinely leads will therefore be regulated by Gulf authorities on a Gulf timetable.
The Gulf is trying to close it with the one tool it has in abundance: sovereign capital. The PIF, Mubadala, ADQ and QIA are building champions,
founding manufacturers and wielding procurement and headquarters mandates to compel localisation. The effort is genuine and partly working. Multinationals are moving onshore, leading buyers and AI platforms (PureHealth, M42) have been built, and commodity manufacturing has begun. But the deep, high-value device-making stays imported, the scanners and the implants alike, gated by a tiny industrial base, six fragmented markets, and an expatriate-dependent workforce.
The whole argument, in one place, with the evidence behind it.
The Gulf is the world’s great patient. It carries one of the heaviest chronic-disease burdens on earth, diabetes among the world’s highest and cardiovascular disease the leading killer, and it funds the treatment lavishly, the state driving health spending toward $159 billion by 2029. Yet it makes almost none of the devices that treatment needs, importing roughly 94% of them in Saudi Arabia and 98% in the UAE. The defining feature of Gulf medtech is this gap between abundant, state-funded demand and near-total import dependence.
For the maker and the investor, the read is to serve the certain demand and help close the gap. The Gulf will buy whatever it cannot yet make. It
will reward whoever helps it make more, on the sovereign’s terms, one rung of the value curve at a time.
The localisation impulse is regional rather than Saudi alone, and that is easily missed. Every state carries an equivalent programme. There is Vision 2030 in Saudi Arabia, Qatar National Vision 2030, Kuwait Vision 2035, Bahrain's Economic Vision 2030 and Oman Vision 2040. Each treats healthcare as a diversification pillar, and each commits to move up the value chain from buying devices to making them. Only Saudi Arabia has so far converted the commitment into procurement rules, which is the difference between an intention and a lever.
Four corrections carried in this edition sharpen the argument rather than soften it. The diabetes series now rests on the International Diabetes Federation's 11th edition, published in 2025 on 2024 estimates, against a global comparator of 11.1 per cent, with Qatar second ahead of Saudi Arabia. Seha Virtual Hospital connects 241 hospitals and more than 1,400 health centres (Saudi Ministry of Health, 9 August 2026). Device marketing authorisations in the UAE have sat with the Emirates Drug Establishment with
effect from 29 December 2025. The fourth correction concerns procurement. NUPCO's 2026 procurement rules prioritise product that is both SFDA-registered and made in-Kingdom.
Each correction points the same way. The demand is better documented than before, and the digital landscape is larger than reported. The gate is tighter. The sovereign has strengthened its hold on access, while the manufacturing base it is trying to create has not yet materially changed.
Nine conclusions for the people who must act on this market.
The engineering work the sector asks for, and the form it takes on an engagement.
Medical devices are now networked products under regulatory supervision, so the engineering they need sits across security, data and compliance at once. The work below is what device makers, hospital groups and investors in this market commission. Each is delivered by senior engineers working inside the client's own team, with the Global Delivery Centres running what has been built once it is in production.
A device maker or hospital group in this market needs an asset position before it needs a security programme. The register of what is deployed,
by model and by software version, is the document every other decision rests on, and few clients have one that survives inspection. It is a product in its own right, not a spreadsheet exercise. Building it is unglamorous work. Volge usually starts there, because both segmentation and submission evidence are derived from the register rather than assembled separately.
Regulatory evidence is produced continuously or it is reconstructed expensively. Quality management to the international standard for medical devices requires design history and change control to be current, not gathered up for an audit, and the same holds for post-market surveillance (International Organisation for Standardisation, 2016). Volge staffs this with engineers who have filed rather than only advised, and keeps one of them accountable for the record after the programme closes. Continuity matters more than headcount.
The first ninety days should end with a defensible asset register and one segmented clinical network, and nothing more than that, with measurement following from there. Device uptime against maintenance spend is the number a hospital board understands, and time from vulnerability disclosure to fielded patch is the one a regulator asks about. Two failures are common. The register is built once and never maintained, and security is scoped against the corporate network rather than the clinical one behind it.
The bodies cited in this read for market size, disease burden, procurement and regulation, with the year the text attributes to each.
Volge is an engineering firm providing enterprise technology transformation services to clients across the Middle East, India, APAC, Europe, and North America.
Delivery stands on two pillars: Forward Deployed Engineering, with senior specialists embedded in the client’s own team, and Intelligent Command Centre Operations, run from our Global Delivery Centres, which keeps what they build running. Senior engineers stay with an engagement from the first diagnosis through to production.
Our services span Strategy, Data, Platforms, AI and Automation, Cyber Trust, Technology Operations, and Applied Functional Engineering. Engagements begin with a diagnosis. The firm is built on working autonomy: engineers decide, innovate, co-create, and own their work. Motivated engineers build the systems that sustain our clients’ growth.
This edition may be shared with organisations evaluating a Volge engagement. It may not be altered or republished without Volge’s permission, and figures carry their stated basis and date. Volge, Intelligent Command Centre, and Intelligent Command Centre Operations are marks of Volge; other names are the trademarks of their respective owners.